The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent ...

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.” The successful development of the BCL-2 ...

(Memphis, Tenn. – March 18 th, 2024) The life and death of cells are governed by processes that, when disrupted, can lead to cancer. Apoptosis, the process of programmed cell death, is tightly ...

Lunsumio and Polivy showed an 88% overall response rate in relapsed/refractory MCL patients, with high efficacy in high-risk subgroups. The combination therapy was well-tolerated, despite a high ...

This protein, MCL-1, is a powerful agent in regulating cell death – and if levels are lowered, by way of outside forces such as stress, aging, cancer drugs or genetics, HSFCs are left vulnerable and ...

Disrupting apoptosis is a mechanism that cancerous cells use to avoid being killed; this can be performed by overexpressing pro-survival factors, such as induced myeloid leukemia cell differentiation ...

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...

Tuberculosis still kills a lot of people worldwide (1.6 million deaths per year). Previous findings demonstrated that induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reduced the ...